SPDR S&P Biotech ETF faces FDA uncertainty and clinical readouts impacting its equal-weight portfolio.

The SPDR S&P Biotech ETF (XBI) holds over $8 billion in assets with an equal-weight strategy across 150+ biotech companies, making it sensitive to regulatory and clinical events. The new FDA leadership under Marty Makary brings clarity but also concerns about slower drug approvals due to staffing cuts and agency restructuring, which could hurt valuations, especially for smaller firms without commercial revenue. Key clinical readouts from major holdings like Moderna, Krystal Biotech, and Sarepta Therapeutics will significantly influence the fund's performance, as each company has roughly equal weight. The fund's quarterly rebalancing adjusts exposure to winners and losers, with investors advised to watch FDA approval timelines and rebalance outcomes closely through mid-2026 to gauge risk and opportunity.